Literature DB >> 22947360

Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort.

Omid Bakhtar1, Brian A Ference, Lowell A Hedquist, Phillip D Levy, John M Flack.   

Abstract

Resistant hypertension (RH) affects 8% to 30% of hypertensive patients. Blood pressure (BP) reflects the interaction between vascular compliance, resistance to flow, intravascular volume, and cardiac contractility. The relationship of RH with total arterial compliance index (TACI) has not been adequately explored. The RH period prevalence (RH at baseline or follow-up) was determined in a hypertensive cohort (N=156) and compared across quartiles of TACI. Age- and sex-adjusted systolic BP, diastolic BP, and antihypertensive therapeutic intensity score (TIS) were also determined at the time of first BP control. The cohort was 85.3% African American and 67.3% female. Median follow-up was 7 months. The prevalence of RH at baseline was 14.7% while the period prevalence was 43.6%. The period prevalence of RH by ascending quartile for TACI was 66%, 36.8%, 40%, and 30.8% (P=.008). The average BP and antihypertensive TIS at first BP control across TACI quartiles was 122.3/73.4 mm Hg (2.26), 120.7/72.5 mm Hg (1.88), 122.4/75.3 mm Hg (1.71), and 120.0/79.4 mm Hg (1.64) (P=.62, P=.03, P=.13). Low TACI was linked to higher RH prevalence and antihypertensive TIS at first attainment of goal BP according to the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. TACI provides prognostic information that is clinically and perhaps pathophysiologically relevant in RH.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947360      PMCID: PMC8108755          DOI: 10.1111/j.1751-7176.2012.00653.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study.

Authors:  J Redon; C Campos; M L Narciso; J L Rodicio; J M Pascual; L M Ruilope
Journal:  Hypertension       Date:  1998-02       Impact factor: 10.190

3.  Reproducibility of impedance cardiography parameters in outpatients with clinically stable coronary artery disease.

Authors:  Neil Treister; Kevin Wagner; Paul R Jansen
Journal:  Am J Hypertens       Date:  2005-02       Impact factor: 2.689

4.  Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.

Authors:  Eduardo Pimenta; Krishna K Gaddam; Suzanne Oparil; Inmaculada Aban; Saima Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

5.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

6.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Authors:  Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Arch Intern Med       Date:  2008-06-09

7.  Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials.

Authors:  Carlos M Ferrario; John M Flack; John E Strobeck; Gerard Smits; Celine Peters
Journal:  Ther Adv Cardiovasc Dis       Date:  2009-12-30

8.  Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects.

Authors:  Ronald D Smith; Pavel Levy; Carlos M Ferrario
Journal:  Hypertension       Date:  2006-03-06       Impact factor: 10.190

9.  Prognostic influence of office and ambulatory blood pressures in resistant hypertension.

Authors:  Gil F Salles; Claudia R L Cardoso; Elizabeth S Muxfeldt
Journal:  Arch Intern Med       Date:  2008-11-24

10.  Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials.

Authors:  Mirjam J Knol; Ruben G Duijnhoven; Diederick E Grobbee; Karel G M Moons; Rolf H H Groenwold
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

View more
  3 in total

Review 1.  Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.

Authors:  Daniel Glicklich; William H Frishman
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 2.  Resistant Hypertension: A Real Entity Requiring Special Treatment?

Authors:  Stefano Taddei; Rosa Maria Bruno
Journal:  Eur Cardiol       Date:  2016-08

3.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.